A patient who stopped steroids two weeks ago and is now on protonix (omeprazole) and carafate (sucralfate) presents with epigastric pain, vomiting, markedly elevated AST (~600 U/L) and ALT (~550 U/L) and bilirubin of 3.1 mg/dL. What is the appropriate evaluation and management?

Acute Hepatocellular Injury with Elevated Bilirubin: Immediate Evaluation and Management

This patient presents with Grade 3 hepatotoxicity (AST/ALT >5× ULN with bilirubin >3 mg/dL) requiring immediate discontinuation of potentially hepatotoxic medications, comprehensive workup for alternative causes, and consideration of corticosteroid therapy if drug-induced liver injury is confirmed.

Severity Classification and Initial Actions

This patient's laboratory values indicate Grade 3 hepatitis based on ASCO criteria: AST 604 U/L and ALT 557 U/L (both >5× ULN assuming normal upper limit ~40 U/L), with total bilirubin 3.1 mg/dL (>3× ULN) 1. The presence of symptoms (epigastric pain, vomiting) further elevates concern 1.

Immediate Medication Review

Stop all potentially hepatotoxic medications immediately 1:

• Discontinue Protonix (pantoprazole): While rare, PPIs including omeprazole/pantoprazole can cause hepatocellular injury with AST/ALT elevations exceeding 1000 U/L 2. Case reports document symptomatic hepatotoxicity with normalization after discontinuation 2.

• Discontinue Carafate (sucralfate): Though uncommon, sucralfate-associated liver injury has been documented 3. Given the severity of presentation, all non-essential medications should be stopped 1.

• Recent steroid withdrawal: The patient stopped steroids 2 weeks ago. While this timing makes steroid-induced hepatotoxicity less likely, it's important to note that steroid withdrawal itself does not typically cause hepatitis 4.

Comprehensive Diagnostic Workup

Obtain the following tests immediately 1:

Viral and Infectious Causes

• Hepatitis A IgM, Hepatitis B surface antigen (HBsAg), Hepatitis B core antibody IgM, Hepatitis C antibody (consider HCV-RNA if positive) 1
• Consider CMV and EBV serologies 1

Autoimmune and Metabolic Causes

• ANA, anti-smooth muscle antibodies (ASMA), ANCA if suspicion for autoimmune hepatitis 1
• Iron studies (ferritin, transferrin saturation) for hemochromatosis 1
• Ceruloplasmin and 24-hour urine copper if age <40 years (Wilson disease) 5

Imaging

• Right upper quadrant ultrasound with Doppler to evaluate for:
  • Biliary obstruction (though cholestatic pattern less likely given transaminase predominance) 1, 6
  • Hepatic vein thrombosis (Budd-Chiari syndrome) 1
  • Liver metastases or masses 1
  • Hepatic steatosis 6

Additional Laboratory Tests

• Complete metabolic panel including albumin, prothrombin time/INR 5
• Creatine kinase (CK) to exclude rhabdomyolysis as cause of transaminase elevation 1
• Alcohol level and detailed substance use history 1

Management Strategy

Monitoring Intensity

Daily or every-other-day monitoring is required for patients with AST/ALT >8× ULN and/or elevated bilirubin >3× ULN 1. This patient meets criteria with bilirubin 3.1 mg/dL.

Consider inpatient admission for:

• Symptomatic presentation (epigastric pain, vomiting) 1
• Risk of dehydration or electrolyte imbalance 1
• Need for close monitoring of synthetic function (albumin, INR) 5

Corticosteroid Therapy Decision

For Grade 3 hepatitis, corticosteroid initiation depends on etiology 4, 1:

If Drug-Induced Liver Injury (DILI) is Confirmed:

• Start methylprednisolone 1-2 mg/kg/day (typically 1 mg/kg for Grade 3) 4, 1
• Oral prednisone acceptable if patient tolerating oral intake; IV methylprednisolone preferred if concern for upper GI inflammation given epigastric symptoms 1

Steroid-Refractory Cases:

• If no improvement within 2-3 days, add mycophenolate mofetil 500-1000 mg twice daily 4, 1, 7
• Consider liver biopsy to rule out alternative diagnoses (NASH, tumor, cholestatic variants, infection, other autoimmune entities) 1
• Consult hepatology for Grade 3 and above 1

Important Contraindication:

• Do NOT use infliximab for hepatic immune-related adverse events or drug-induced hepatitis 1

Steroid Taper Protocol

Once transaminases improve to ≤Grade 1 (AST/ALT <3× ULN) 1:

• Begin taper over 4-6 weeks 4, 1
• Monitor liver function tests every 3 days during taper 1
• Re-escalate if enzymes rise again 1

Differential Diagnosis Considerations

Most Likely Causes Given Clinical Context:

1. Drug-induced hepatotoxicity (PPI or sucralfate): Hepatocellular pattern (AST/ALT predominant over alkaline phosphatase) with recent medication exposure 2, 3

2. Ischemic hepatitis: Consider if patient has cardiovascular risk factors; typically presents with dramatic transaminase elevations (often >1000 U/L) 1

3. Acute viral hepatitis: Requires serologic confirmation 1

4. Autoimmune hepatitis: Can present acutely; check autoantibodies 1

Less Likely but Must Exclude:

• Acute Budd-Chiari syndrome: Ultrasound with Doppler will evaluate hepatic vein patency 1
• Acute biliary obstruction: Less likely given transaminase-predominant pattern, but imaging needed 6

Clinical Pitfalls to Avoid

1. Do not delay stopping potentially hepatotoxic medications while awaiting workup results 1, 8

2. Do not assume recent steroid use is the cause: Steroids typically cause mild transaminase elevations, not this degree of injury 4

3. Do not start empiric corticosteroids before excluding infection: Viral hepatitis serologies must be sent first 1

4. Monitor synthetic function closely: Rising bilirubin with coagulopathy signals potential acute liver failure requiring urgent hepatology consultation and possible transfer to transplant center 1, 5

5. Epigastric symptoms may indicate concurrent gastritis/upper GI inflammation: Consider upper endoscopy if symptoms persist, though not urgent unless GI bleeding suspected 1